Hero

Press Releases

Press Releases

Royalty Pharma to Present at Evercore ISI 4th Annual Healthconx Virtual Conference

NEW YORK, NY, November 29, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4 th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET.   The webcast will be accessible from Royalty Pharma’s

Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and Orladeyo from Biocryst Pharmaceuticals

NEW YORK, NY and RESEARCH TRIANGLE PARK, NC, November 22, 2021 Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.

Royalty Pharma Reports Third Quarter 2021 Results

NEW YORK, NY, November 10, 2021 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).

Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021

NEW YORK, NY, October 18, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

Royalty Pharma Declares Fourth-Quarter 2021 Dividend

NEW YORK, NY, October 15, 2021 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinary share. The dividend will be paid on December 15, 2021, to shareholders of record at the close of business

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, NY, September 3, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m.

Royalty Pharma Reports Second Quarter 2021 Results

NEW YORK, NY, August 11, 2021 -  Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).

Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021

NEW YORK, NY, July 19, 2021 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter of 2021 financial results on Wednesday, August 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

Royalty Pharma Declares Third-Quarter 2021 Dividend

NEW YORK, NY, July 16, 2021 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share. The dividend will be paid on September 15, 2021, to shareholders of record at the close of business on

Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

NEW YORK, NY, July 15, 2021 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.3 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 2.15% Senior Notes due 2031 (the “Social Bonds”)
Displaying 1 - 10 of 82